Skip to main content

Table 4 Characteristics of qualitative studies included (N = 15)

From: Medication adherence in pregnant women with human immunodeficiency virus receiving antiretroviral therapy in sub-Saharan Africa: a systematic review

S/N Author: Year Country: Setting Study design Participants and type of PMTCT intervention implemented Sample size QAR of studies
1 *Kiarie, et al. 2003 [30] Kenya: Urban FGDs HIV+ pregnant and postpartum women enrolled in a clinical trial in a tertiary HF.
7 FGDs (4 sessions with pregnant women and 3 sessions with postpartum women). ****
2 *Bancheno, et al. 2010 [28] Swaziland:
IDIs HIV + pregnant women registered for PMTCT services in a rural HF: Nurses, nurse assistants.
64 Interviews (nurses and nurse assistants) ***
3 Duff, et al.2010 [39] Uganda: Urban and rural IDIs and FGDs HIV + mothers registered in PMTCT programme.
45 IDIs; 1 FGD (8 women). ****
4 *Mepham, et al. 2011 [38]. South Africa: Rural IDIs HIV + pregnant women receiving PMTCT services in a HF.
20 interviews ****
5 Ujiji, et al. 2011 [45] Kenya: Rural Narratives HIV + pregnant women already receiving ART in two HFs.
28; 12 urban and 16 rural. ***
6 Buesseler, et al. 2014 [42] Cote d’Ivoire:Rural IDIs HIV + mothers registered in PMTCT integration programme at four HFs: HCWs.
IDIs:24 women,5 HCWs. ***
7 Gourlay, et al. 2014 [59] Tanzania: Rural PLA and IDIs HIV + women attending four HF for PMTCT services: HIV- women: HCWs: Health officials.
(specific short course antiretroviral regimen not mentioned)
61 PLA (3male, 3 female groups with 8–12 participants): 30 IDIs (16 HIV + &5 HIV – women, 6 HCWs, 3 health officials. ****
8 Kastner, et al. 2014 [51] Uganda: Urban IDIs Women attending HIV clinic for follow up (HIV + pregnant women in their 2ND AND 3RD trimester.
IDIs:25 pregnant women ***
9 *Murithi, et al. 2015 [41] Kenya: IDIs HIV + women pregnant receiving care in a PMTCT clinic.
(specific short course antiretroviral regimen not mentioned)
IDIs:15 pregnant women **
10 Elwell, 2016 [43] Malawi: Urban and rural. IDIs and FGDs HIV + pregnant women in a PMTCT programme at four HFs: Community leaders: HCWs.
IDIs(25 women,19HCWs and 32 community leaders);FGDs(53 women, 32 community leaders) ***
11 *Granato, et al. 2016 [78] Cote d’ Ivoire: Urban and Rural. IDIs HIV positive pregnant women enrolled in PMTCT services attending 30 HFs.
30 key informant interviews ****
12 Katirayi, et al., 2016 [56] Malawi: Urban, peri-urban and rural. IDIs and FGDs HIV + pregnant and postpartum women enrolled in a PMTCT programme: HCWs.
39IDIs (19 pregnant women and 20 postpartum women): 16 FGDs (4 pregnant women, 4 HCWs, and 8 postpartum women). ****
13 Kim, et al. 2016 [44] Malawi: Urban and rural. IDIs HIV + pregnant women and postpartum attending ANC at four HF offering ART services.
65IDIs ****
14 *Napua, et al. 2016 [40] Mozambique: Urban IDIs and FGDs HIV + women pregnant registered in 6 high volume HFs providing PMTCT and ART services: HCWS.
49 IDIs (8 at 5 sites, and 9 at 1 site): 12 FGDs (ANC patients: 1 FGD per site with 5–10 participants, and with HCWs (1 per site with 6–9 participants). ****
15 O’Gorman, et al. 2010 [55] Malawi: Rural IDIs and FGDs Ante/post-natal women, fathers, grandmothers, TBAs, health workers, community leaders.
(specific short course antiretroviral regimen not mentioned)
26 interviews(4 antenatal women, 5 grandmothers, 4HCWs, 5 traditional birth attendants, 3 fathers, 3 church leaders, 2 chiefs): 5 FGDs in total(29 antenatal women in 3 FGDs, 6 postnatal women in 1 FGD, 9 fathers in 1 FGD. ****
  1. *Qualitative aspect of a mixed method study: S/N also indicate study number, the sequential order of articles on this table and on Table 1; differs from the bibliographic reference number: QAR Quality assessment rating of studies, IDI In-depth interviews, FGD Focus group discussion, Narratives Narrative structuring, TBA Traditional birth attendants, HCWs Health care workers, NC Antenatal clinic, HF Health facility, PMTCT Prevention of mother to child transmission of HIV, ART Antiretroviral therapy, cART Combination antiretroviral therapy(triple drug combination). Quality assessment rating of studies: using the mixed methods appraisal tool an overall quality score of (*) in one of the four methodological assessment area represent 25%; (****) = all four criteria met